Quantcast

Latest Beta secretase Stories

Double Whammy From Brain Enzyme For Alzheimer's Disease
2012-08-20 08:22:40

Sanford-Burnham researchers discover that an enzyme known for generating toxic brain plaques in Alzheimer's disease also causes additional memory and cognitive deficits via a separate mechanism The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease...

2012-07-26 06:53:33

(Ivanhoe Newswire) — New research using mice and post-mortem samples of brains from patients with Alzheimer's disease found that a single event of a moderate-to-severe traumatic brain injury (TBI) can disrupt proteins that regulate an enzyme associated with Alzheimer's. The study reveals the complex mechanisms that result in a rapid and robust post-injury elevation of the enzyme, BACE1, in the brain. These results could lead to the development of a drug treatment that targets this...

2012-07-25 13:00:38

A study, performed in mice and utilizing post-mortem samples of brains from patients with Alzheimer's disease, found that a single event of a moderate-to-severe traumatic brain injury (TBI) can disrupt proteins that regulate an enzyme associated with Alzheimer's. The paper, published in The Journal of Neuroscience, identifies the complex mechanisms that result in a rapid and robust post-injury elevation of the enzyme, BACE1, in the brain. These results may lead to the development of a drug...

2012-07-25 06:37:29

(Ivanhoe Newswire) — New research using mice and post-mortem samples of brains from patients with Alzheimer's disease found that a single event of a moderate-to-severe traumatic brain injury (TBI) can disrupt proteins that regulate an enzyme associated with Alzheimer's. The study reveals the complex mechanisms that result in a rapid and robust post-injury elevation of the enzyme, BACE1, in the brain. These results could lead to the development of a drug treatment that targets this...

2012-07-19 04:20:02

Tokyo, July 19, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that the first data from clinical studies with E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor discovered and being developed in-house as a treatment for Alzheimer's disease, were presented during oral sessions at the Alzheimer's Association International Conference (AAIC) 2012.Beta-amyloid (Abeta) deposition in the brain is thought to be one of causes of Alzheimer's disease, and it is...

2012-07-13 08:20:01

Tokyo, July 13, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that first data from clinical studies with E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor discovered in-house, will be presented during oral sessions at the Alzheimer's Association International Conference (AAIC) 2012, taking place in Vancouver, Canada from July 14 to 19, 2012. E2609 is a BACE inhibitor currently being developed by Eisai as a next-generation oral Alzheimer's disease...

shutterstock_104922437
2012-07-13 07:06:17

Connie K. Ho for redOrbit.com - Your Universe Online 5 million. That´s the number of people in the U.S. suffering from Alzheimer´s disease, according to a recent CNN article. Scientists recently announced that they had discovered a gene that fights Alzheimer´s. This is a positive step forward as the gene could help develop treatments to fight the disorder. In the journal Nature, researchers explained how the gene that caused an early form of Alzheimer´s could also be...

2012-03-08 01:03:09

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients. The study has been published in the online edition of the Journal of Alzheimer's Disease. According to...

2012-02-21 06:06:12

(Ivanhoe Newswire) -- Recent research has shown that Alzheimer's drugs, which are in clinical trials still, have adverse side effects. The drugs are designed to prevent BACE1, the enzyme Robert Vassar originally discovered that promotes the development of clumps of plaque associated with Alzheimer's.  BACE1 cuts up and releases proteins that form the plaque, making those who developed the drug believe that by blocking the enzyme the development of Alzheimer's disease might slow down....


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.